William G. Roche

Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC.